Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart and Insulin Lispro.

The rapid-acting insulin analogs aspart and lispro have now been developed in biphasic formulations.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, open-label and crossover.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Being open-label, the Insulin Aspart study did not mask who received what.

In the crossover set-up each of the participants took both Insulin Aspart and the comparison in turn, acting as their own control.

BIAsp 30 and Mix25 were injected subcutaneously immediately before a test meal, and BHI 30 was injected 15 min before a test meal.

The primary target of analysis was serum glucose excursion 0-5 h after a meal.

What Was Measured

The subject headings attached to it are Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin, Insulin Aspart and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Aspart and Insulin Lispro.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.